首页> 中文期刊> 《中国医药指南》 >超声最大径线测量在乳腺癌新辅助化疗疗效评价中的价值

超声最大径线测量在乳腺癌新辅助化疗疗效评价中的价值

         

摘要

目的:观察多普勒超声测量病灶最大径线在乳腺癌新辅助化疗疗效评估中的应用价值。方法利用多普勒超声对91例接受新辅助化疗治疗前与治疗后的乳腺癌病灶最大径线进行测量,并与术后组织病理检查结果对比。结果化疗疗效的总有效率为74.73%,总的无效率为25.27%;超声组对其总体疗效的评价为74.7%,与病理组的评价标准(86.8%)相比稍低;而对其亚组分析后发现乳腺导管癌(P<0.05),晚期Ⅲ期患者(P<0.05),内分泌有反应型的患者(0.042),其超声的评价标准不能达到病理标准,且差异具有统计学意义;而对于小叶癌(P>0.05),早期的乳腺癌(Ⅰ+Ⅱ)患者(P>0.05),内分泌无反应型的患者(P>0.05),使用超声评价化疗疗效可以达到与病理评价类似的效果;其次肿块的大小不会影响超声评价的准确性。结论单纯使用超声测量最大径线的方法对乳腺癌新辅助化疗效果评估具有一定的作用。%Objective To investigate the application of doppler ultrasound in the evaluation of the effect of neoadjuvant chemotherapy of breast cancer. Methods Using doppler ultrasonography in 91 cases that have received neoadjuvant chemotherapy of breast cancer to measure maximum diameters and Comparre with postoperative pathological ifndings. Results The total effective rate of chemotherapy was 74.73%and total inefifciency is 25.27%;The evaluation of curative effect for ultrasound group is 74.7%thich is lower than that of pathological group (86.8%);Results of subgroup analysis showed that ultrasonic evaluation standard can not reach the standard pathology for those patients with mammary ductal carcinoma (P<0.05), adanced stageⅢ(P<0.05) and endocrine (0.042), however, ultrasonic evaluation standard have similarly Effect with pathology standard for those patients with lobular carcinoma (P>0.05), early breast cancer (Ⅰ+Ⅱ) (P>0.05), no reactive endocrine of patients (P>0.05);ifnally, lump size will not affect the accuracy of the ultrasonic evaluation. Conclusion The single use of ultrasonic measurement of maximum diameter line to evaluate effect of neoadjuvant chemotherapy for breast cancer is is limited, So we must Combine with other methods to assess the chemotherapeutic efifcacy.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号